A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of sustained-release quetiapine fumarate (Seroquel) compared with placebo in the treatment of generalized anxiety disorder.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Dec 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quetiapine (Primary)
Indications Generalised anxiety disorder
Focus Therapeutic Use
Acronyms TITANIUM
Sponsors AstraZeneca

Most Recent Events

06 Dec 2011 Results from a pooled analysis published in the Human Psychopharmacology: Clinical and Experimental.
18 Jun 2011 Results published in the Journal of Clinical Psychopharmacology.
28 Jun 2009 Planned pooled analysis of data from the GOLD, SILVER and TITANIUM trials presented at the 9th World Congress of Biological Psychiatry.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight